Metabolomics Market Expected to Reach $6 Billion by 2030 | CAGR of 12.2%

According to a new report published by Allied Market Research, titled, “Metabolomics Market by Product and Service, Application and Indication: Global Opportunity Analysis and Industry Forecast, 2021–2030,"the global metabolomics market size was valued at $2,032 Million in 2020, and is estimated to reach $6,663 Million by 2030, growing at a CAGR of 12.2% from 2021 to 2030.

Metabolomics includes the application of a variety of analytical methods such as spectroscopy, chromatography, and multivariate analysis for identification of quantification of various metabolites. The analytical methods facilitate classification of a multitude of known and unknown metabolites in the reaction. The comprehensive nature of metabolites can be applied in many fields and assist in the development of new treatment and diagnostics in human diseases.

Owing to increased adoption of metabolomics in precision medicine and upsurge in R&D investment metabolomics market is expected to grow at a productive rate in the analysis period. Moreover, technological advancement in auxiliary medical devices and growth in demand for the development of quality medications is expected to fuel the market. However, the high cost of medical devices and lack of effective data management obstruct the growth of metabolomics market.

The global metabolomics market is segmented based on product & service, application, indication, and region. Based on product & service, it is divided into metabolomics instruments and metabolomics bioinformatics tools & services. The metabolomics instruments segment is further divided into separation techniques and detection techniques. The separation techniques segment is further classified into high-performance liquid chromatography, gas chromatography, ultra-performance liquid chromatography, and capillary electrophoresis. The detection techniques segment is further categorized into mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis.

The metabolomics bioinformatics tools & services segment is further bifurcated into bioinformatics tools & databases and bioinformatics services. Based on application, the metabolomics market is categorized into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. Based on indication, it is divided into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The COVID-19 was declared as a pandemic in the start of the year 2020. This was followed with strict lockdowns and containment restriction in more than 200 countries across the globe. Hence, this led to serious disruptions in every business across each industry globally. For instance, the lockdowns restrictions lead to closure of non-essential business worldwide. Only, the essential businesses such as healthcare facilities with COVD-19 focus operated during the pandemic.

COVID-19 exhibited a positive impact on metabolomics market. This was due to the fact that metabolomics was vastly applied in the research related to studying the effect of COVID-19 on human body. Metabolomics were used to analyze alterations in the plasma metabolone which reflected the clinical presentation of COVID-19 patients. Hence, the rise in demand for metabolomics products during COVID-19 led to surge in growth of metabolomics market thereby exhibiting a positive impact on the market.

By product segment, the largest market for metabolomics is metabolomics bioinformatics due to a huge number of utilization in metabolomics analysis tool and services. Owing to increased demand for data management, it is anticipated to grow at the highest CAGR during the forecast period.

By application segment the largest market in metabolomics is biomarker discovery due to technological advancement in discovery technologies, an upsurge in incidences of chronic diseases, increase in demand for personalized healthcare, and growth in recognitions for modern diagnostics tests.

Key Findings of the Study

• By product, the metabolomics bioinformatics tool and services segment was the highest contributor to the metabolomics market in 2020.
• On the basis of application, the biomarker discovery segment dominated the market in 2020, personalized medicine is expected to continue this trend during the forecast period.
• Depending on indication, cancer segment led the market in 2020; neurological disorder market is anticipated to grow at the highest CAGR during the forecast period.
• Region wise, North America garnered the largest revenue share in 2020, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.